Summary:
- Patient Capital Management, LLC increased its position in Precigen by 10.2 million shares during Q3 2025.
- The fund now holds approximately 26.5 million shares of Precigen, worth $87.06 million.
- Precigen develops gene and cellular therapies, disease-modifying therapeutics, and has proprietary platforms like UltraVector and UltraCAR-T.
Patient Capital Management, LLC recently boosted its stake in Precigen by acquiring 10.2 million additional shares during the third quarter of 2025. This move increased the fund’s total holding to around 26.5 million shares, valued at $87.06 million. Precigen, a company specializing in gene and cellular therapies, as well as disease-modifying therapeutics, operates under a business model that focuses on research, development, and strategic collaborations in the biotechnology and healthcare sectors. With cutting-edge platforms like UltraVector and UltraCAR-T, Precigen aims to address complex medical needs in oncology and regenerative medicine.
Furthermore, Precigen’s stock price has seen a significant surge, up by 375.91% over the past year, outperforming the S&P 500 by 356.34 percentage points. This growth can be attributed to the FDA’s full approval of Papzimeos, the only drug approved to treat recurrent respiratory papillomatosis (RRP). This rare and potentially life-threatening disease affects a limited population, but with new treatment options like Papzimeos becoming available, the addressable market could expand. Patient Capital’s investment in Precigen has proven fruitful, with the stock price rising by 191.5% since June 30, 2025. This strategic move showcases the fund’s confidence in Precigen’s potential for growth and success in the biotechnology and healthcare industries.
